USC researchers have received a five-year NIH grant of up to $3.2 million to investigate how the hormone thymulin regulates age-related inflammation, or inflammaging, and whether it can improve responses to cancer immunotherapy. Building on earlier findings that thymulin helps suppress chronic inflammation and may enhance treatment effectiveness in older mice, the team will study its molecular mechanisms and therapeutic potential in aged mouse models of breast cancer and melanoma, as well as in human cells. The project aims to clarify how aging alters the immune system and to identify new strategies that could help older patients respond better to immunotherapy and potentially combat metastatic cancer.

Dr. Aaron Schimmer officially steps into his role as President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today, marking a new chapter for cancer research in the province.

Schimmer brings a wealth of scientific, clinical, strategic and operational expertise to lead OICR. An internationally recognized hematologist, blood cancer scientist and research leader, he most recently served as Director of Research at University Health Network’s (UHN) Princess Margaret Cancer Centre, where he is also a longtime clinician-scientist.

As President and Scientific Director of OICR, Schimmer will lead the Institute and deliver on OICR’s provincial mandate to accelerate cancer research in Ontario for better health and a stronger economy.

New research from the University of Oklahoma demonstrates how an aggressive form of breast cancer co-opts the body’s own immune system to attract nerves that fuel tumor growth.

About the Study: In this cohort study of a diverse population of women, ultrasound completion rates were lower among Black women, primarily due to fibroids impairing endometrial visibility. Nevertheless, transvaginal sonography demonstrated a 76% completion rate and retained excellent ability to exclude cancer in Black women, regardless of fibroid presence.

A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine. The discovery points to a possible solution to the problem of BTK inhibitor treatment resistance.

CAMBRIDGE, Mass. — Aug 4, 2026 — Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the publication of a collaborative study in the journal npj Precision Oncology. The peer-reviewed paper demonstrates how advanced artificial intelligence combined with comprehensive multi-omic analysis can successfully identify promising therapeutic targets in one of the rarest and least understood forms of head and neck cancer.

A new study led by Swansea University has laid bare the devastating impact that soaring infant formula milk prices are having on the health, finances, and mental wellbeing of UK parents and their children.

AMHERST, Mass. — Radiopharmaceutical therapy (RPT) has made great strides over the last 50 years, having only recently received FDA approval to treat prostate cancer. But despite the progress—and billions of dollars of industry investments—one area that has lagged behind is dosing, which is still one-size-fits-all. Now, researchers at the University of Massachusetts Amherst have developed an AI model that can inform treatment individualization by generating a patient’s radiation dose map that matches gold-standard accuracy in under 23 seconds.